News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
300,087 Results
Type
Article (14728)
Company Profile (102)
Press Release (285257)
Multimedia
Podcasts (52)
Webinars (10)
Section
Business (96750)
Career Advice (583)
Deals (17577)
Drug Delivery (68)
Drug Development (39499)
Employer Resources (60)
FDA (7286)
Job Trends (6824)
News (165235)
Policy (15133)
Tag
Academia (551)
Accelerated approval (2)
Adcomms (6)
Allergies (41)
Alliances (25781)
ALS (45)
Alzheimer's disease (446)
Antibody-drug conjugate (ADC) (52)
Approvals (7326)
Artificial intelligence (131)
Autoimmune disease (10)
Automation (5)
Bankruptcy (158)
Best Places to Work (4922)
BIOSECURE Act (10)
Biosimilars (59)
Biotechnology (45)
Bladder cancer (27)
Brain cancer (17)
Breast cancer (97)
Cancer (799)
Cardiovascular disease (79)
Career advice (492)
Career pathing (12)
CAR-T (39)
Cell therapy (135)
Cervical cancer (5)
Clinical research (33315)
Collaboration (399)
Compensation (187)
Complete response letters (17)
COVID-19 (845)
CRISPR (23)
C-suite (131)
Cystic fibrosis (44)
Data (809)
Denatured (15)
Depression (12)
Diabetes (97)
Diagnostics (1843)
Digital health (1)
Diversity (2)
Diversity, equity & inclusion (17)
Drug discovery (66)
Drug pricing (69)
Drug shortages (12)
Duchenne muscular dystrophy (38)
Earnings (36375)
Editorial (13)
Employer branding (9)
Employer resources (52)
Events (42453)
Executive appointments (416)
FDA (7810)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (255)
Gene editing (45)
Generative AI (10)
Gene therapy (120)
GLP-1 (360)
Government (1411)
Grass and pollen (3)
Guidances (24)
Healthcare (4591)
Huntington's disease (4)
IgA nephropathy (13)
Immunology and inflammation (40)
Indications (16)
Infectious disease (885)
Inflammatory bowel disease (60)
Inflation Reduction Act (7)
Influenza (15)
Intellectual property (51)
Interviews (73)
IPO (7091)
IRA (29)
Job creations (2131)
Job search strategy (441)
Kidney cancer (6)
Labor market (12)
Layoffs (188)
Leadership (4)
Legal (3654)
Liver cancer (22)
Lung cancer (105)
Lymphoma (74)
Machine learning (3)
Management (18)
Manufacturing (175)
MASH (33)
Medical device (2426)
Medtech (2429)
Mergers & acquisitions (10756)
Metabolic disorders (286)
Multiple sclerosis (35)
NASH (14)
Neurodegenerative disease (27)
Neuropsychiatric disorders (10)
Neuroscience (684)
NextGen: Class of 2025 (2021)
Non-profit (776)
Now hiring (8)
Obesity (161)
Opinion (126)
Ovarian cancer (27)
Pain (54)
Pancreatic cancer (17)
Parkinson's disease (61)
Partnered (7)
Patents (131)
Patient recruitment (34)
Peanut (14)
People (30464)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8876)
Phase II (14208)
Phase III (12400)
Pipeline (540)
Policy (74)
Postmarket research (1450)
Preclinical (3585)
Press Release (26)
Prostate cancer (50)
Psychedelics (12)
Radiopharmaceuticals (124)
Rare diseases (191)
Real estate (2852)
Recruiting (23)
Regulatory (10977)
Reports (15)
Research institute (647)
Resumes & cover letters (99)
Rett syndrome (4)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (45)
Series B (17)
Service/supplier (3)
Sickle cell disease (36)
Special edition (6)
Spinal muscular atrophy (81)
Sponsored (7)
Startups (1759)
State (2)
Stomach cancer (4)
Supply chain (32)
Tariffs (32)
The Weekly (35)
Vaccines (172)
Venture capitalists (15)
Weight loss (101)
Women's health (8)
Worklife (4)
Date
Today (73)
Last 7 days (321)
Last 30 days (1056)
Last 365 days (13572)
2025 (4488)
2024 (14449)
2023 (16409)
2022 (22367)
2021 (23204)
2020 (21874)
2019 (17271)
2018 (13540)
2017 (15366)
2016 (14526)
2015 (17287)
2014 (13651)
2013 (11705)
2012 (12773)
2011 (13306)
2010 (12088)
Location
Africa (349)
Alabama (15)
Alaska (1)
Arizona (61)
Arkansas (5)
Asia (21600)
Australia (2986)
California (2144)
Canada (1041)
China (260)
Colorado (98)
Connecticut (102)
Delaware (75)
Europe (42475)
Florida (367)
Georgia (45)
Idaho (11)
Illinois (236)
India (16)
Indiana (150)
Iowa (1)
Japan (99)
Kansas (63)
Kentucky (13)
Louisiana (5)
Maine (4)
Maryland (324)
Massachusetts (1796)
Michigan (38)
Minnesota (114)
Missouri (29)
Montana (8)
Nebraska (7)
Nevada (13)
New Hampshire (22)
New Jersey (892)
New Mexico (9)
New York (603)
North Carolina (419)
North Dakota (2)
Northern California (941)
Ohio (66)
Oklahoma (4)
Oregon (18)
Pennsylvania (530)
Puerto Rico (8)
Rhode Island (10)
South America (540)
South Carolina (3)
Southern California (848)
Tennessee (38)
Texas (333)
United States (8773)
Utah (54)
Virginia (79)
Washington D.C. (31)
Washington State (166)
Wisconsin (25)
300,087 Results for "vertex pharmaceuticals incorporated".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pain
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still believes in the promise of its candidate as Vertex Pharmaceuticals’ first-in-class drug Journavx opens up the non-opioid space.
February 18, 2025
·
3 min read
·
Tristan Manalac
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.
March 31, 2025
·
4 min read
·
Annalee Armstrong
Pain
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
February 24, 2025
·
9 min read
·
Tristan Manalac
Pain
Vertex Eyes Expansive, Easy Access for Journavx in Coming Weeks
Vertex expects to make the newly approved non-opioid pain medicine Journavx available by the end of February.
February 11, 2025
·
2 min read
·
Tristan Manalac
Legal
HHS Says Vertex is ‘Grasping at Straws’ With Casgevy Fertility Suit
Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes.
January 16, 2025
·
2 min read
·
Tristan Manalac
Pain
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy
Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their concerns as the company’s share price fell 13% in premarket trading.
December 19, 2024
·
2 min read
·
Tristan Manalac
Genetown
Vertex to Participate in Upcoming June Investor Conferences
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
May 22, 2024
·
2 min read
Press Releases
Vertex to Announce First Quarter 2025 Financial Results on May 5th
April 7, 2025
·
1 min read
Press Releases
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
March 31, 2025
·
7 min read
Business
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex’s cell therapies for type 1 diabetes.
April 23, 2024
·
4 min read
1 of 30,009
Next
